Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage immuno-oncology company developing genetically engineered, off-the-shelf allogeneic T cell therapies for cancer and autoimmune diseases. Its product candidates use healthy-donor T cells engineered to target cancer cells or disease-causing immune cells,… From the company’s description.
Over the twelve months to Sep 30, 2026, Allogene Therapeutics, Inc. reported revenue of $4.64M and a net loss of $174.46M. Operations used $108.63M in cash. In fiscal 2025, it reported a net loss of $190.89M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Allogene Therapeutics, Inc. does
In the company’s own words
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage immuno-oncology company developing genetically engineered, off-the-shelf allogeneic T cell therapies for cancer and autoimmune diseases. Its product candidates use healthy-donor T cells engineered to target cancer cells or disease-causing immune cells, with the goal of creating treatments available for use across patients. The company’s three core programs are cema-cel, a CD19-targeting therapy being studied as first-line consolidation for large B-cell lymphoma; ALLO-316, a CD70-targeting candidate for renal cell carcinoma; and ALLO-329, a dual CD19- and CD70-targeting candidate for systemic lupus erythematosus, idiopathic inflammatory myopathies, and systemic sclerosis. Its Dagger® technology is incorporated in ALLO-329 and is designed to reduce rejection of infused cells. Allogene manufactures clinical product candidates at its Cell Forge 1 facility in California. The company’s development platform builds on assets acquired from Pfizer in 2018 and licensing agreements for gene-editing technologies, including TALEN® and CRISPR-based approaches. Its website is https://www.allogene.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1737287
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Allogene Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Allogene Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Allogene Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Allogene Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Allogene Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”